Tonix Pharmaceuticals Successfully Uplists to Nasdaq Global Select Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Should l Buy TNXP?
Source: Globenewswire
- Successful Uplisting: Tonix Pharmaceuticals has received Nasdaq approval to transfer its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading expected to commence on March 3, 2026, signifying the company's compliance with higher financial and corporate governance standards.
- Enhanced Market Recognition: This uplisting is anticipated to increase Tonix's visibility among institutional investors, improve liquidity, and broaden market recognition, potentially leading to higher trading volumes and a wider investor base.
- Strategic Milestone: CEO Seth Lederman stated that this uplisting represents an important milestone for Tonix, as the company aims to leverage this enhanced platform to drive growth and create value for shareholders, reflecting its financial and operational growth.
- Product Line Expansion: Tonix focuses on CNS and immunology treatments, with its new drug TONMYA providing the first new therapy for fibromyalgia in over 15 years, showcasing the company's potential in addressing high unmet medical needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNXP
Wall Street analysts forecast TNXP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.980
Low
65.00
Averages
67.50
High
70.00
Current: 13.980
Low
65.00
Averages
67.50
High
70.00
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tonix Pharmaceuticals to Present Tonmya at AAPM Annual Meeting
- New Drug Presentation: Tonix Pharmaceuticals will showcase its new drug Tonmya™ at the 2026 American Academy of Pain Medicine (AAPM) Annual Meeting, marking the first new treatment for fibromyalgia in over 15 years, which is expected to attract significant industry attention.
- Clinical Outcomes: Research indicates that TNX-102 SL produces clinically meaningful improvements in patient-centered outcomes, further validating its potential in treating fibromyalgia and potentially driving market demand.
- Conference Details: The poster will be presented on March 6, 2026, at 4:55 PM in Salt Lake City, with Dr. Errol Gould, Vice President of Medical Affairs at Tonix, as the presenter, likely drawing interest from numerous professionals.
- Product Line Expansion: Tonix is also conducting clinical trials for other drugs, including those targeting major depressive disorder and acute stress disorder, demonstrating the company's broad positioning in the CNS field and future growth potential.
See More
Tonix Pharmaceuticals Shares Decline Post Nasdaq Uplisting
- Nasdaq Uplisting: Tonix Pharmaceuticals commenced trading on the Nasdaq Global Select Market on March 3, 2026, reflecting compliance with higher financial and corporate governance standards, which may enhance visibility among institutional investors and improve liquidity.
- CEO Statement: CEO Seth Lederman emphasized that this uplisting is a significant milestone, indicating the company's commitment to driving growth and creating shareholder value, suggesting that Tonix has achieved notable financial and operational progress that could lead to increased trading volumes and better access to institutional investors.
- Stock Trend: Currently, Tonix Pharmaceuticals shares are down 2% at $13.70 during premarket trading, and the stock is trading 9.8% below its 20-day simple moving average, indicating a bearish trend in the short term and reflecting ongoing challenges in the stock's performance.
- Technical Indicators: The relative strength index (RSI) is at 44.45, considered neutral, indicating that the stock is neither overbought nor oversold, while the MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure on the stock, resulting in mixed momentum in performance.
See More
Tonix Pharmaceuticals Successfully Uplists to Nasdaq Global Select Market
- Successful Uplisting: Tonix Pharmaceuticals has received Nasdaq approval to transfer its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading expected to commence on March 3, 2026, signifying the company's compliance with higher financial and corporate governance standards.
- Enhanced Market Recognition: This uplisting is anticipated to increase Tonix's visibility among institutional investors, improve liquidity, and broaden market recognition, potentially leading to higher trading volumes and a wider investor base.
- Strategic Milestone: CEO Seth Lederman stated that this uplisting represents an important milestone for Tonix, as the company aims to leverage this enhanced platform to drive growth and create value for shareholders, reflecting its financial and operational growth.
- Product Line Expansion: Tonix focuses on CNS and immunology treatments, with its new drug TONMYA providing the first new therapy for fibromyalgia in over 15 years, showcasing the company's potential in addressing high unmet medical needs.
See More
Tonix Pharmaceuticals Successfully Uplists to Nasdaq Global Select Market
- Successful Uplisting: Tonix Pharmaceuticals has received Nasdaq approval to transfer its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading expected to commence on March 3, 2026, reflecting the company's compliance with higher financial and corporate governance standards.
- Enhanced Market Recognition: This uplisting is expected to increase Tonix's visibility among institutional investors, improve liquidity, and broaden market recognition, potentially leading to increased trading volumes and greater value creation for shareholders.
- Strategic Development Milestone: CEO Seth Lederman stated that this uplisting represents an important milestone for the company, as Tonix aims to leverage this enhanced platform to drive growth and create shareholder value, demonstrating confidence in its future prospects.
- Product Line Expansion: Tonix focuses on CNS and immunology treatments, with its new drug TONMYA™ providing the first new therapy for fibromyalgia in over 15 years, further solidifying its market position in the biotechnology sector.
See More
Tonix Pharmaceuticals Reports Positive Phase 3 Clinical Data for TONMYA
- Successful Phase 3 Trial: Tonix Pharmaceuticals presented positive data for TONMYA at the Non-Opioid Pain Therapeutics Summit in Boston, demonstrating its significant pain reduction capabilities, thereby reinforcing its position as a non-opioid treatment option.
- Patient Recruitment and Study Design: The RESILIENT trial was a 14-week, randomized, double-blind, placebo-controlled study conducted at 34 U.S. sites, enrolling 456 participants who met the 2016 American College of Rheumatology criteria for fibromyalgia, ensuring the reliability of the results.
- Side Effects and Tolerability: TONMYA was well tolerated, with a discontinuation rate due to adverse events of 6.1% in the treatment group compared to 3.5% in the placebo group, and most adverse events were mild oral reactions, indicating its safety profile.
- Market Outlook and Approval Information: TONMYA received FDA approval in August 2025 and became commercially available in the U.S. in November 2025, marking the first new prescription medicine for fibromyalgia in over 15 years, expected to meet the treatment needs of over 10 million adults in the U.S.
See More
TONMYA Shows Significant Pain Reduction in Fibromyalgia Treatment
- Clinical Trial Results: At the 2026 Non-Opioid Pain Therapeutics Summit, TONMYA demonstrated a statistically significant reduction in weekly average pain scores at Week 14 (p<0.0001) compared to placebo in the RESILIENT study, with an effect size of 0.38, indicating its efficacy in treating fibromyalgia.
- Unique Dosing Method: TONMYA's sublingual formulation is designed for nighttime administration, bypassing first-pass metabolism to optimize drug exposure during sleep while limiting daytime exposure to the active metabolite, enhancing the overall treatment experience for patients.
- Good Tolerability: The study showed that TONMYA was well tolerated, with an adverse event-related discontinuation rate of 6.1%, lower than the 3.5% for placebo, and the most common adverse events were mild oral reactions, indicating a favorable safety profile.
- Market Demand Alignment: With over 10 million adults in the U.S. affected by fibromyalgia and existing treatments often limited by tolerability, the introduction of TONMYA provides an effective non-opioid alternative, addressing the urgent market need for new therapies.
See More
Tonix Pharmaceuticals to Present Tonmya at AAPM Annual Meeting
- New Drug Presentation: Tonix Pharmaceuticals will showcase its new drug Tonmya™ at the 2026 American Academy of Pain Medicine (AAPM) Annual Meeting, marking the first new treatment for fibromyalgia in over 15 years, which is expected to attract significant industry attention.
- Clinical Outcomes: Research indicates that TNX-102 SL produces clinically meaningful improvements in patient-centered outcomes, further validating its potential in treating fibromyalgia and potentially driving market demand.
- Conference Details: The poster will be presented on March 6, 2026, at 4:55 PM in Salt Lake City, with Dr. Errol Gould, Vice President of Medical Affairs at Tonix, as the presenter, likely drawing interest from numerous professionals.
- Product Line Expansion: Tonix is also conducting clinical trials for other drugs, including those targeting major depressive disorder and acute stress disorder, demonstrating the company's broad positioning in the CNS field and future growth potential.
See More
Tonix Pharmaceuticals Shares Decline Post Nasdaq Uplisting
- Nasdaq Uplisting: Tonix Pharmaceuticals commenced trading on the Nasdaq Global Select Market on March 3, 2026, reflecting compliance with higher financial and corporate governance standards, which may enhance visibility among institutional investors and improve liquidity.
- CEO Statement: CEO Seth Lederman emphasized that this uplisting is a significant milestone, indicating the company's commitment to driving growth and creating shareholder value, suggesting that Tonix has achieved notable financial and operational progress that could lead to increased trading volumes and better access to institutional investors.
- Stock Trend: Currently, Tonix Pharmaceuticals shares are down 2% at $13.70 during premarket trading, and the stock is trading 9.8% below its 20-day simple moving average, indicating a bearish trend in the short term and reflecting ongoing challenges in the stock's performance.
- Technical Indicators: The relative strength index (RSI) is at 44.45, considered neutral, indicating that the stock is neither overbought nor oversold, while the MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure on the stock, resulting in mixed momentum in performance.
See More
Tonix Pharmaceuticals Successfully Uplists to Nasdaq Global Select Market
- Successful Uplisting: Tonix Pharmaceuticals has received Nasdaq approval to transfer its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading expected to commence on March 3, 2026, signifying the company's compliance with higher financial and corporate governance standards.
- Enhanced Market Recognition: This uplisting is anticipated to increase Tonix's visibility among institutional investors, improve liquidity, and broaden market recognition, potentially leading to higher trading volumes and a wider investor base.
- Strategic Milestone: CEO Seth Lederman stated that this uplisting represents an important milestone for Tonix, as the company aims to leverage this enhanced platform to drive growth and create value for shareholders, reflecting its financial and operational growth.
- Product Line Expansion: Tonix focuses on CNS and immunology treatments, with its new drug TONMYA providing the first new therapy for fibromyalgia in over 15 years, showcasing the company's potential in addressing high unmet medical needs.
See More
Tonix Pharmaceuticals Successfully Uplists to Nasdaq Global Select Market
- Successful Uplisting: Tonix Pharmaceuticals has received Nasdaq approval to transfer its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading expected to commence on March 3, 2026, reflecting the company's compliance with higher financial and corporate governance standards.
- Enhanced Market Recognition: This uplisting is expected to increase Tonix's visibility among institutional investors, improve liquidity, and broaden market recognition, potentially leading to increased trading volumes and greater value creation for shareholders.
- Strategic Development Milestone: CEO Seth Lederman stated that this uplisting represents an important milestone for the company, as Tonix aims to leverage this enhanced platform to drive growth and create shareholder value, demonstrating confidence in its future prospects.
- Product Line Expansion: Tonix focuses on CNS and immunology treatments, with its new drug TONMYA™ providing the first new therapy for fibromyalgia in over 15 years, further solidifying its market position in the biotechnology sector.
See More
Tonix Pharmaceuticals Reports Positive Phase 3 Clinical Data for TONMYA
- Successful Phase 3 Trial: Tonix Pharmaceuticals presented positive data for TONMYA at the Non-Opioid Pain Therapeutics Summit in Boston, demonstrating its significant pain reduction capabilities, thereby reinforcing its position as a non-opioid treatment option.
- Patient Recruitment and Study Design: The RESILIENT trial was a 14-week, randomized, double-blind, placebo-controlled study conducted at 34 U.S. sites, enrolling 456 participants who met the 2016 American College of Rheumatology criteria for fibromyalgia, ensuring the reliability of the results.
- Side Effects and Tolerability: TONMYA was well tolerated, with a discontinuation rate due to adverse events of 6.1% in the treatment group compared to 3.5% in the placebo group, and most adverse events were mild oral reactions, indicating its safety profile.
- Market Outlook and Approval Information: TONMYA received FDA approval in August 2025 and became commercially available in the U.S. in November 2025, marking the first new prescription medicine for fibromyalgia in over 15 years, expected to meet the treatment needs of over 10 million adults in the U.S.
See More
TONMYA Shows Significant Pain Reduction in Fibromyalgia Treatment
- Clinical Trial Results: At the 2026 Non-Opioid Pain Therapeutics Summit, TONMYA demonstrated a statistically significant reduction in weekly average pain scores at Week 14 (p<0.0001) compared to placebo in the RESILIENT study, with an effect size of 0.38, indicating its efficacy in treating fibromyalgia.
- Unique Dosing Method: TONMYA's sublingual formulation is designed for nighttime administration, bypassing first-pass metabolism to optimize drug exposure during sleep while limiting daytime exposure to the active metabolite, enhancing the overall treatment experience for patients.
- Good Tolerability: The study showed that TONMYA was well tolerated, with an adverse event-related discontinuation rate of 6.1%, lower than the 3.5% for placebo, and the most common adverse events were mild oral reactions, indicating a favorable safety profile.
- Market Demand Alignment: With over 10 million adults in the U.S. affected by fibromyalgia and existing treatments often limited by tolerability, the introduction of TONMYA provides an effective non-opioid alternative, addressing the urgent market need for new therapies.
See More
